Christophe HURET
Lab Manager / Research Assistant (IGE Université Paris Diderot)
Equipe : ARNs non-codants, Différenciation et Développement
Téléphone : +33 1 57 27 89 29
Pièce n°: 426

Christophe obtained his Master in ”Cellular and Molecular Biology Speciality Immunotechnologies and biotherapies” at Pierre et Marie Curie University (Paris 6) in 2005. He was recruited as engineer in David Klatzmann lab (CHU La Pitié Salpétriêre) to develop a new genetic vaccine to protect against HCV virus. In parallel, he worked on Compuvac project during 5 years to standardize different immunologic tests in order to compare different vectors (AAV, VLP, Lentivirus, DNA …).
He joined Claire Rougeulle’s team in 2011 and works on human X inactivation .
He is also responsible for the Paris Diderot Vectorology platform.
On his spare time, Christophe enjoys playing badminton and tennis.


  • Furlan G, Gutierrez Hernandez N, Huret C, Galupa R, van Bemmel JG, Romito A, Heard E, Morey C, Rougeulle C. The Ftx Noncoding Locus Controls X Chromosome Inactivation Independently of Its RNA Products. Mol Cell. 2018 Apr 20. pii: S1097-2765(18)30227-2.
  • Vallot C., Patrat C., Collier AJ., Huret C., Casanova M., Liyakat Ali TM., Tosolini M., Frydman N., Heard E., Rugg-Gunn P.J.and Rougeulle C. Competing action of XIST and XACT noncoding RNAs in the control of X chromosome activity during human early development. Cell Stem Cell. 2017 Jan 5;20(1):102-111.
  • Dérian D, Bellier B, Pham HP, Tsitoura E, Kazazi D, Huret C, Mavromara P, Klatzmann D, Six A. (2016) Early transcriptome signatures from immunized mouse dendritic cells predict late vaccine-induced T-cell responses. PLOS Computational Biology, 2016 Mar 21;12(3):e1004801
  • Vallot C., Huret C, Lesecque Y., Resch A., Oudrhiri N., Bennaceur-Griscelli A., Duret L. and Rougeulle C. (2013). XACT, a long non-coding transcript coating the active X chromosome in human pluripotent cells. Nat Genet. 2013 Mar ;45(3):239-41
  • Lescaille G.*, Pitoiset F.*, Macedo R., Baillou C., Huret C, Klatzmann D., Tartour E., Lemoine FM.**, Bellier B.** . (2013) Efficacy of DNA vaccines forming E7 recombinant retroviral virus-like particles for the treatment of HPV-induced cancers. Human Gene Therapy 2013 May ;24(5):533-44
  • Huret C, Desjardins D, Miyalou M, Levacher B, Amadoudji Zin M, Bonduelle O, Combadière B, Dalba C, Klatzmann D, Bellier B. Vaccine (2013) Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice. Vaccine. 2013 Mar 1 ;31(11):1540-7
  • Bellier B*, Huret C*, Miyalou M, Desjardins D, Frenkiel MP, Despres P, Tangy F, Dalba C, Klatzmann D.(2009) DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine. 2009 Vol27(42):5772-80. *co-first authors.
  • Desjardins D, Huret C, Dalba C, Kreppel F, Kochanek S, Cosset FL, Tangy F, Klatzmann D, Bellier B. (2009) Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development. J Gene Med. 2009 Apr ;11(4):313-25.